Observational studyWiener medizinische Wochenschrift (1946)2025
Non-alcoholic steatohepatitis incidence in patients with psoriasis vulgaris.
Observational study in Wiener medizinische Wochenschrift (1946), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsNon-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), characterized by hepatic inflammation and damage due to fat accumulation. Psoriasis patients show higher NASH incidence due to overlapping risk factors like obesity and insulin resistance. The study aimed to determine the incidence of non-alcoholic steatohepatitis in patients with psoriasis vulgaris.
methodsThis cross-sectional observational study included 80 adult patients diagnosed with psoriasis vulgaris. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI) score. All participants underwent abdominal ultrasonography to assess liver steatosis. Those with significant findings suggestive of fatty liver were further evaluated with transient elastography (FibroScan, EchoSens, Paris, France) to determine liver stiffness and controlled attenuation parameter (CAP) values.
resultsAmong psoriatic patient diagnosed with NASH, the mean PASI score was 8.8 ± 3.6 which was higher than those diagnosed with NAFLD and non-NASH non-NAFLD patients (6.7 ± 4.5 and 7.1 ± 3.9, respectively); however, this difference was not statistically significant (P = 0.19). The percentage of moderate and severe psoriasis was higher in NASH patients (68.75%) compared to NAFLD and non-NASH non-NAFLD subjects (57.1% and 46.5%, respectively).
conclusionNASH and NAFLD are linked to psoriasis severity and systemic metabolic dysfunction. Future studies with larger cohorts and prospective designs are needed to validate these findings and explore underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.